Induction Therapy With Daclizumab in Heart Transplantation-How Many Doses?

Transplantation Proceedings

Volumn 38, Issue 8, 2006, Pages 2541-2543

  Ortiz, V ^a   Almenar, L ^a   Martinez Dolz L ^a   Zorio, E ^a   Chamorro, C ^a   Moro, J ^a   Aguero J ^a   Rueda, J ^a   Arnau, M A ^a   Salvador, A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CHI SQUARE TEST; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STUDENT T TEST; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; SURVIVAL ANALYSIS;

EID: 33750619569     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.08.024     Document Type: Article

References (8)

1. Bernard J.L. A review of interleukin-2 receptor antagonist in solid organ transplantation. Pharmacotherapy 19 (1999) 1127
2. Webster A.C., Playford E.G., and Higgins G. Interleukin 2 receptor antagonist for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77 (2004) 166
3. Beniaminovitz A., Itescu S., and Lietz K. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342 (2000) 613
4. Kobashigawa J., David K., and Morris J. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine and corticosteroids. Transplant Proc 37 (2005) 1333
5. Cuppoletti A., Pérez-Villa F., and Vallejos I. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation. Transplant Proc 37 (2005) 4036
6. Joyal D. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation. Clin Transplant 18 (2004) 493
7. Vicenti F., Lantz M., and Birnbaum J. A phase-1 trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 63 (1997) 33
8. Hershberger R., Starling R., and Eisen H. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352 (2005) 2705